Results 101 to 110 of about 10,751 (182)

Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma.

, 2015
Ramucirumab is a fully humanized monoclonal antibody targeting the extracellular domain of the VEGF receptor 2. It prevents ligand binding to VEGF receptor 2 and receptor-mediated pathway activation in endothelial cells.
Hofheinz, Ralf-Dieter;Lorenzen, Sylvie
core   +1 more source

Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors

, 2017
Lessons Learned Ramucirumab was well tolerated in Chinese patients with advanced solid tumors, and adverse events were manageable in this study.
Zhiyu Chen, Jin Wang, Dongmei Ji, Amanda Long, Baoyue Li, Haidong Chi, Junning Cao, Ling Gao, Weina Shen, Jin Li   +9 more
core   +1 more source

Erlotinib Plus Ramucirumab Therapy After Osimertinib Treatment: A Multicenter Observational Study

Clinical Medicine Insights: Oncology
Background Although osimertinib is widely used and is the most recommended drug worldwide for epidermal growth factor receptor (EGFR) -mutated lung cancer, treatment strategies post-osimertinib failure remain unclear.
Kosuke Hamai MD, PhD, Yuka Kato MD, PhD, Kenichi Chikamori MD, PhD, Nobuhisa Ishikawa MD, PhD, Shoichi Kuyama MD, PhD, Kakuhiro Yamaguchi KD, PhD, Kenichiro Kudo MD, PhD, Hiroyasu Shoda MD, PhD, Koji Inoue MD, PhD, Yoshifumi Nishimura MD, PhD, Nagio Takigawa MD, PhD, Shoichiro Yamamoto MD, PhD, Mari Uno MD, Naoki Kinoshita MD, PhD   +13 more
doaj   +1 more source

Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy [PDF]

Docetaxel +/- ramucirumab remains the standard-of-care therapy for patients with metastatic non-small-cell lung cancer (NSCLC) after progression on platinum doublets and immune checkpoint inhibitors (ICIs). The aim of our study was to investigate whether
Kunal Rai, Natalie Vokes, Jianjun Zhang, Padmakumar, Priyadharshini, Hong, Lingzhi, Jaffray, David A, Caroline Chung, Xiuning Le, Hubert, Shawna M, John V. Heymach, J. Jack Lee, Vokes, Natalie, Woodman, Scott E, Chung, Caroline, Kaiwen Wang, Yanyan Lou, Kang Qin, David A. Jaffray, Li, Shenduo, Scott E. Woodman, Altan, Mehmet, Priyadharshini Padmakumar, Ara Vaporciyan, Vaporciyan, Ara, Waree, Rinsurongkawong, Lou, Yanyan, Don L. Gibbons, Mehmet Altan, Lingzhi Hong, Qin, Kang, Lee, J Jack, Shenduo Li, Rinsurongkawong Waree, Rai, Kunal, Zhang, Jianjun, Shawna M. Hubert, Le, Xiuning, Heymach, John V, Wang, Kaiwen, Gibbons, Don L   +39 more
core   +1 more source

Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors

, 2016
PURPOSE: The objective of this phase II study was to evaluate the potential of pharmacokinetic (PK) drug-drug interactions between ramucirumab and irinotecan or its metabolite, SN-38, when administered with folinic acid and 5-fluorouracil (FOLFIRI ...
Lee, James J, Shepard, Dale R, Gao, Ling, Nasroulah, Federico, Braiteh, Fadi, Lin, Yong, LoRusso, Patricia, Wang, Ding, Denlinger, Crystal S, Asakiewicz, Christopher, Chaudhary, Archana   +10 more
core   +1 more source

Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma

, 2019
TPS4150 Background: Ramucirumab is used for treatment of metastatic gastroesophageal adenocarcinoma after disease progression on first-line chemotherapy. Superior survival outcome is expected when combined with paclitaxel.
Trikalinos, Nikolaos, Pedersen, Katrina, Sanjeevaiah, Aravind, Suresh, Rama, Amin, Manik A, Wang-Gillam, Andrea, Park, Haeseong, Huffman, Jesse, Bagegni, Nusayba Ali, Lockhart, A. Craig, Lim, Kian-Huat, Nixon, Andrew B, Tan, Benjamin R   +12 more
core   +1 more source

Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDA. [PDF]

ESMO Gastrointest Oncol
Inagaki C, Oki E, Ando K, Hirano H, Furuta M, Narita Y, Esaki T, Murotani K, Kawakami H, Muro K.   +9 more
europepmc   +1 more source

New drugs: Ramucirumab

Australian Prescriber, 2016
openaire   +2 more sources

Second-line treatment selection for advanced hepatocellular carcinoma: a network meta-analysis with reconstructed survival curves and integrated benefit-risk assessment. [PDF]

Front Immunol
Li X, Nie G, Wang Y, Xu J, Yang J, He E, Liu G, Li B, Lu J.   +8 more
europepmc   +1 more source

Discordant Cavitary Changes: A Radiological Dilemma in Invasive Mucinous Adenocarcinoma: A Case Report. [PDF]

Respirol Case Rep
Nigi A, Miya N, Iwamoto K, Itani H, Kondou S.   +4 more
europepmc   +1 more source